Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.45 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

zeltia sa (ZLIXF) Key Developments

Zeltia Announces Earnings Results for the First Half of 2015

Zeltia announced earnings results for the first half of 2015. For the period, the company reported total net revenues of EUR 84.4 million, a 7.8% increase compared with the same period of 2014. The company obtained EUR 9.5 million in EBITDA compared with EUR 22 million in the same period of 2014. The company reported EUR 3.33 million in net attributable profit compared with EUR 17.7 million in the first half of 2014, which represents an 80% profit drop.

Zeltia SA to Report Q2, 2015 Results on Jul 28, 2015

Zeltia SA announced that they will report Q2, 2015 results on Jul 28, 2015

Zeltia SA, Annual General Meeting, Jun 30, 2015

Zeltia SA, Annual General Meeting, Jun 30, 2015., at 11:30 Eastern Daylight. Location: Instituto Ferial de Vigo (IFEVI) site on Avenida del Aeropuerto, 772, Cotogrande -. 36318- Vigo.

Zeltia Reports Earnings Results for the First Quarter of 2015

Zeltia reported earnings results for the first quarter of 2015. For the period, the company's net profit dropped 61% to EUR 6.5 million (USD 7.1 million) compared with EUR 16.9 million in the equivalent period of 2014. Net sales in the biopharmaceutical sector amounted to EUR 21.1 million, compared with EUR 20.9 million in first-quarter 2014. The main reason for Zeltia's negative financial performance during the beginning of the year is the reduction in milestone payment under an agreement signed with Janssen in 2011 on the development of oncology product Yondelis, which for first-quarter 2015 corresponded to only USD 10 million, compared with USD 25 million in first-quarter 2014.

Zeltia SA Presents at UBS Global Healthcare Conference, May-18-2015

Zeltia SA Presents at UBS Global Healthcare Conference, May-18-2015 . Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: José-Luis Moreno, IR & Capital Markets Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZLIXF:US $4.45 USD 0.00

ZLIXF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZLIXF.
View Industry Companies
 

Industry Analysis

ZLIXF

Industry Average

Valuation ZLIXF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 3,977.8x
TEV/Sales 4.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZELTIA SA, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.